The cancer drug business is quite a profitable one. A “high risk, high reward” proposition has been the narrative for those in research and development (R&D). Successes, marketing, patent protection and discovery cost money. Failures cost money. Not pursuing a different path with a failure or even a success costs money. As does lost revenue while performing R&D. 

Can an accurate dollar value even be placed on what it takes from idea conception through utilization to develop a new drug? Due to the opaque nature of the industry’s disclosures, a new study published in JAMA Internal Medicine sought to quantify a standard amount by focusing on new cancer drugs and analyzing the...

On November 8, I published an article titled, "Whoever Wins On Election Day 2016, American Science Is Still #1 In The World." That is every bit as true now as it was then.

Mr. Trump promised to be a different kind of president. So, nobody should be surprised that he is living up to his campaign pledges. However, his budget proposal for 2018 should raise some serious concerns. Cutting science funding, particularly that of the NIH, is not aligned with his goal to "Make America Great Again."

How Bad Are the Proposed Cuts?

In many ways, Mr. Trump's goal of reducing the size and scope of the federal bureaucracy is...